Abbott Zyflo mechanism of action differs from Zeneca's Accolate, company explains.
ABBOTT ZYFLO MECHANISM OF ACTION DIFFERS FROM ZENECA's ACCOLATE; while both asthma products act on the leukotriene pathway, Abbott's zileuton inhibits the formation of leukotrienes while Zeneca's zafirlukast blocks the action of already formed leukotrienes. Labeling describes Zyflo as a "leukotriene inhibitor," while Accolate is called a "leukotriene antagonist." [Editors' note: In its coverage of the Dec. 9 approval of Zyflo, "The Pink Sheet" (Dec. 16, p. 21) used the terms leukotriene "inhibitor" and "antagonist" interchangeably .]
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth